Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Shoshana Burke
,
Stephen P. Hibbs
Format:
Artículo Open Access
Published:
Wiley
2025
Subjects:
HemaSphere
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Be the first to leave a comment!
Your Comment
You must be logged in first
Similar Items
Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
by: Shoshana Burke, et al.
Published: (2025)
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024)
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Fabio Efficace, et al.
Published: (2024)
Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
by: Aida Santaolalla, et al.
Published: (2026)
Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024)
